AlphAIalphai — Financial news for AI agents
Stock TitanMAR 314 min read$RNXT

Cancer device reaches 12 U.S. centers as RenovoRx readies trial finish

RenovoRx reported full-year 2025 revenue of $1.1 million for its RenovoCath device, a significant increase from 2024, with 12 U.S. cancer centers actively utilizing the device and 21 more evaluating it. The company's Phase III TIGeR-PaC trial is on track for enrollment completion by mid-2026, with final data anticipated in 2027. RenovoRx also strengthened its financial position with a $10 million private placement, bringing its cash on hand to approximately $13 million.

Original reporting
Stock Titan
Published Mar 31, 2026, 2:40 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Mar 31, 2026, 3:00 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Cancer device reaches 12 U.S. centers as RenovoRx readies trial finish — source image
Source · Stock Titan
Decision brief

The 30-second read

$RNXTBullishMed
01

Why it matters

The positive developments are likely to support stock appreciation, but risks remain from clinical trial uncertainties and market competition.

02

Market read

The news is highly relevant for investors interested in biotech and medical device sectors, especially those focusing on cancer therapies.

03

What to watch

Regulatory hurdles, competitive landscape, and broader market volatility could influence outcomes.

Timing: Immediate to short-term (next 1-3 months) due to ongoing clinical trial and revenue updates.

Background

RenovoRx is advancing its cancer treatment device, with recent revenue growth and clinical trial progress indicating increasing adoption.

Company-level read

Ticker impact

$RNXTBullishHigh confidence
Context

High relevance due to recent revenue growth and clinical trial progress.

Expected impact

Moderate upward movement over the next 3-6 months.

Evidence & confidence

The increase in revenue, expansion to 12 U.S. centers, and progress in Phase III trial indicate strong growth prospects, likely supporting stock appreciation.

Market effects

Sector

Positive impact on the medical devices and cancer treatment sectors, potentially boosting related stocks.

Regional

Primarily U.S.-focused, with potential influence on regional biotech and healthcare markets.

Global

Limited; primarily relevant within the U.S. healthcare and biotech sectors.

Counterpoint

What could challenge this read

Potential delays or setbacks in clinical trial completion could negatively impact stock performance.

Key entities

  • Company
    RenovoRx Inc.

    Developer of cancer treatment devices, focusing on minimally invasive therapies.

  • Product
    RenovoCath device

    A device used in cancer treatment, showing increased adoption and revenue.

  • Clinical Trial
    Phase III TIGeR-PaC trial

    A pivotal trial for the company's main product, on track for completion in 2026.

Read at source← All news

Related articles

AUG 14
$RNXTMed

RenovoRx Q2 Earnings Call Highlights

RenovoRx (NASDAQ:RNXT) reported Q2 gross profit of $766,000 and ~84% gross margin. Operating loss was ~$3.4M and net loss per share was $0.06. Cash fell to ~$9.5M at June 30. The company narrowed FY2026 revenue guidance to $3.75M-$4.25M and expects cash-flow break-even in Q4 2027. Phase III TIGeR-PaC enrollment is complete; initial data expected H2 2027.

yahoo.com6 min
AUG 13
$RNXTMedAI 8/10

RenovoRx (RNXT) Q2 2026 Earnings Call Transcript

RenovoRx (RNXT) reported Q2 2026 revenue of $909,000, up 115% year over year, and raised full-year 2026 guidance to $3.75 million to $4.25 million. The company said it completed Phase III TIGeR-PaC enrollment, had 78 survival events vs 86 required, and expects initial results in H2 2027. Cash was $9.5 million at June 30, 2026.

fool.com6 min
AUG 11
$RNXTMed

RenovoRx, Inc.: RenovoRx Achieves Major Milestone with Full Enrollment in Phase III TIGeR-PaC Trial for Locally Advanced Pancreatic Cancer

RenovoRx (Nasdaq: RNXT) said it has completed enrollment in its Phase III TIGeR-PaC trial for locally advanced pancreatic cancer. Trial enrollment is closing as of Aug. 7, 2026, with completion expected in 1H 2027 after 86 deaths events, and 78 events reported as of Aug. 11. Initial top-line data is expected in 2H 2027; primary endpoint is overall survival.

finanznachrichten.de2 min
MAY 28
$RNXTMedAI 9/10

RenovoRx Says FDA Grants Orphan Drug Status For Oxaliplatin To Treat Pancreatic Cancer

RenovoRx said the FDA granted orphan drug designation for oxaliplatin to treat pancreatic cancer. The company said it is its second such designation in pancreatic cancer and third overall, supporting its RenovoCath targeted intra-arterial delivery approach. RenovoRx previously received ODD for intra-arterial gemcitabine via RenovoCath. In pre-market trading, RNXT was $0.93.

rttnews.com3 min
MAY 28
$RNXTMedAI 9/10

RenovoRx Announces FDA Orphan Drug Designation Granted: Oxaliplatin for the Treatment of Pancreatic Cancer

RenovoRx (Nasdaq: RNXT) said the FDA granted orphan drug designation for oxaliplatin to treat pancreatic cancer, under Section 526. The company said the designation is its second in pancreatic cancer and third overall, and would provide seven years of market exclusivity plus a 25% tax credit on qualified clinical research and an FDA application fee waiver. RenovoRx is also advancing its Phase III TIGeR-PaC trial and commercializing RenovoCath.

manilatimes.net4 min
MAY 26
$RNXTMedAI 8/10

RenovoRx Announces Promising Pharmacokinetic Data Using the TAMP™ Platform Presented at the 2026 ASCO Annual Meeting

RenovoRx said a Phase III TIGeR-PaC PK/pharmacodynamic sub-study abstract was published for the 2026 ASCO meeting. The study in 16 patients compared intra-arterial gemcitabine via its TAMP/RenovoCath system (IAG) versus IV gemcitabine, reporting lower systemic gemcitabine and higher inactive metabolite levels, with a correlation to reduced CA 19-9. The company expects full enrollment in June 2026 and final readout mid-to-late 2027.

manilatimes.net4 min